Status:
COMPLETED
Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Type II Diabetes Mellitus
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
This study will use Continuous Glucose Monitoring to assess differences in glycemic profiles between vildagliptin and glimepiride.
Eligibility Criteria
Inclusion
- Type 2 diabetes patients on stable metformin
- 18-70 years old
- Willing to perform at least 4 capillary blood glucose tests per day
Exclusion
- Type 2 diabetes patients on any other antidiabetic treatment
- Patients listed in other trials
- Patients with significant diabetic organ disease or complications.
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01262586
Start Date
November 1 2010
End Date
March 1 2011
Last Update
November 18 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Mainz, Germany